You just read:

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

News provided by

Agenus Inc.

Nov 30, 2016, 08:50 ET